Lucid Diagnostics Stock (NASDAQ:LUCD)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$1.05

52W Range

$0.63 - $1.58

50D Avg

$0.85

200D Avg

$0.93

Market Cap

$53.99M

Avg Vol (3M)

$253.36K

Beta

1.42

Div Yield

LUCD Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 14, 2021

Website

LUCD Performance

LUCD Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$2.43M	$377.00K	$500.00K
Operating Income	$-48.48M	$-56.17M	$-27.42M
Net Income	$-52.67M	$-56.17M	$-28.74M
EBITDA	$-45.98M	$-54.23M	$-27.41M
Basic EPS	$-1.26	$-1.55	$-1.54
Diluted EPS	$-1.26	$-1.55	$-1.54

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 24Aug 12, 24 | 1:32 PM

Q1 24May 13, 24 | 12:00 AM

Q4 23Mar 26, 24 | 4:27 PM

Peer Comparison

Ticker	Company
FNA	Paragon 28, Inc.
IRMD	IRadimed Corporation
OFIX	Orthofix Medical Inc.
ITGR	Integer Holdings Corporation
LUNG	Pulmonx Corporation
CLPT	ClearPoint Neuro, Inc.
NPCE	NeuroPace, Inc.
SRDX	Surmodics, Inc.
LIVN	LivaNova PLC
KIDS	OrthoPediatrics Corp.
OSA	ProSomnus, Inc. Common Stock
XAIR	Beyond Air, Inc.
NARI	Inari Medical, Inc.
CVRX	CVRx, Inc.